Psoriatic Arthritis Specialist in Duluth, MN

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease that affects roughly 30% of people who have psoriasis — the skin condition characterized by red, scaly patches. It is not simply “arthritis that comes with psoriasis.” It is a distinct autoimmune disease in which the immune system attacks healthy joint tissue, causing pain, swelling, and, if left untreated, permanent joint damage. If you have psoriasis and are experiencing joint pain, swelling, or morning stiffness, Dr. Adam Elisha, DO — a board-certified rheumatologist in Duluth, MN — provides comprehensive psoriatic arthritis evaluation and treatment at St. Luke’s Rheumatology Associates.

What Is Psoriatic Arthritis?

Psoriatic arthritis is an autoimmune condition in which the immune system mistakenly attacks the joints, tendons, and surrounding structures. Inflammation can affect any joint in the body, including the spine, and is often asymmetric — meaning it may affect different joints on each side of the body. In some patients, joint symptoms appear before skin psoriasis is visible, which can make diagnosis challenging without a rheumatologist’s evaluation.

PsA is classified into five patterns, each with distinct features:

Asymmetric oligoarthritis — few joints affected, not mirrored on both sides
Symmetric polyarthritis — multiple joints on both sides, similar to rheumatoid arthritis
Distal interphalangeal (DIP) predominant — primarily affects the joints closest to the fingernails and toenails
Spondylitis — inflammation of the spine causing back pain and stiffness
Arthritis mutilans — a severe, destructive form that can cause deformity

Signs and Symptoms of Psoriatic Arthritis

Common symptoms that should prompt evaluation by a rheumatologist include:

Joint pain, swelling, or stiffness — particularly in the morning
Sausage-like swelling of an entire finger or toe (dactylitis)
Pain at the heel or sole of the foot (enthesitis — inflammation where tendons attach to bone)
Nail changes: pitting, ridging, or separation of the nail from the nail bed (onycholysis)
Low back or buttock pain that improves with movement and worsens with rest
Fatigue
Eye inflammation (uveitis) — redness, pain, or blurred vision

Diagnosing Psoriatic Arthritis

There is no single blood test that confirms psoriatic arthritis. Diagnosis is clinical and based on a combination of findings:

History and physical examination: Joint pattern, skin and nail involvement, family history of psoriasis or PsA
Imaging: X-rays to assess joint damage; MRI or ultrasound to detect early inflammation and enthesitis before structural damage occurs
Laboratory tests: Rheumatoid factor is typically negative in PsA (seronegative); HLA-B27 may be positive in axial disease; inflammatory markers (CRP, ESR) help gauge disease activity
CASPAR criteria: A validated classification tool combining skin, nail, joint, and imaging findings used to confirm the diagnosis

Psoriatic Arthritis Treatment Options

Psoriatic arthritis is a treat-to-target disease — meaning the goal is to achieve remission or minimal disease activity, and medications are adjusted until that goal is met. The choice of treatment depends on the severity and pattern of joint involvement, the extent of skin disease, and individual patient factors.

NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen or celecoxib can reduce pain and stiffness in mild disease, particularly when the spine is involved. They do not, however, prevent joint damage and are not adequate as sole therapy in moderate-to-severe PsA.

Conventional DMARDs

Methotrexate is the most commonly used conventional disease-modifying antirheumatic drug (cDMARD) for psoriatic arthritis and is effective for both joint and skin disease. Leflunomide and sulfasalazine are alternatives used in peripheral joint disease.

Biologic DMARDs

Biologic medications have transformed the treatment of psoriatic arthritis. Several classes are available:

TNF inhibitors: adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), certolizumab (Cimzia), golimumab (Simponi) — effective for joints, skin, and enthesitis
IL-17 inhibitors: secukinumab (Cosentyx), ixekizumab (Taltz) — particularly effective for axial disease and skin
IL-23 inhibitors: guselkumab (Tremfya), risankizumab (Skyrizi) — newer agents with strong efficacy and favorable safety profiles
IL-12/23 inhibitor: ustekinumab (Stelara)
T-cell costimulation blockade: abatacept (Orencia)

JAK Inhibitors

Oral JAK inhibitors including upadacitinib (Rinvoq) and tofacitinib (Xeljanz) are approved for psoriatic arthritis and offer an alternative to injectable biologics, particularly for patients with peripheral joint disease.

Why Early Treatment Matters

Like rheumatoid arthritis, psoriatic arthritis can cause irreversible joint damage if inflammation is not controlled. Studies show that patients who begin appropriate DMARD therapy within the first few months of symptom onset have significantly better long-term outcomes — including less radiographic damage and better physical function. If you have psoriasis and joint symptoms, early rheumatology evaluation is important even if symptoms seem mild.

Related Rheumatology Resources

Psoriatic Arthritis Care in Duluth, MN

Dr. Adam Elisha, DO, provides individualized psoriatic arthritis care at St. Luke’s Rheumatology Associates in Duluth, MN. With fellowship training at the University of Pittsburgh Medical Center (UPMC) and a focus on inflammatory arthritis and spondyloarthropathy, Dr. Elisha offers expert evaluation and access to the full range of biologic and targeted synthetic therapies available for PsA.

To schedule an evaluation, call (218) 249-6960, Monday through Friday, 8:00 AM – 4:00 PM.

St. Luke’s Rheumatology Associates
1000 E 1st St, Suite 302
Duluth, MN 55805